Kestra Private Wealth Services LLC Reduces Position in Moderna, Inc. (NASDAQ:MRNA)

Kestra Private Wealth Services LLC lessened its holdings in shares of Moderna, Inc. (NASDAQ:MRNA) by 3.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 5,090 shares of the company’s stock after selling 177 shares during the quarter. Kestra Private Wealth Services LLC’s holdings in Moderna were worth $506,000 at the end of the most recent quarter.

A number of other large investors have also recently modified their holdings of the company. Allworth Financial LP boosted its holdings in shares of Moderna by 6.5% in the fourth quarter. Allworth Financial LP now owns 1,660 shares of the company’s stock valued at $165,000 after purchasing an additional 101 shares during the period. TIAA Trust National Association boosted its holdings in shares of Moderna by 2.3% in the fourth quarter. TIAA Trust National Association now owns 4,491 shares of the company’s stock valued at $447,000 after purchasing an additional 102 shares during the period. Sound Income Strategies LLC boosted its holdings in shares of Moderna by 17.8% in the fourth quarter. Sound Income Strategies LLC now owns 762 shares of the company’s stock valued at $76,000 after purchasing an additional 115 shares during the period. Bay Colony Advisory Group Inc d b a Bay Colony Advisors boosted its holdings in shares of Moderna by 6.5% in the fourth quarter. Bay Colony Advisory Group Inc d b a Bay Colony Advisors now owns 2,459 shares of the company’s stock valued at $245,000 after purchasing an additional 151 shares during the period. Finally, Bristlecone Advisors LLC boosted its holdings in shares of Moderna by 2.6% in the fourth quarter. Bristlecone Advisors LLC now owns 5,999 shares of the company’s stock valued at $597,000 after purchasing an additional 153 shares during the period. Hedge funds and other institutional investors own 75.33% of the company’s stock.

Analyst Upgrades and Downgrades

MRNA has been the subject of a number of research reports. Needham & Company LLC reiterated a “hold” rating on shares of Moderna in a report on Thursday, May 2nd. Jefferies Financial Group restated a “buy” rating and set a $125.00 target price on shares of Moderna in a report on Tuesday, April 9th. HSBC restated a “reduce” rating and set a $86.00 target price (up previously from $75.00) on shares of Moderna in a report on Monday, February 26th. Royal Bank of Canada upped their target price on Moderna from $125.00 to $135.00 and gave the stock an “outperform” rating in a report on Friday. Finally, Canaccord Genuity Group upped their target price on Moderna from $91.00 to $106.00 and gave the stock a “hold” rating in a report on Friday. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $129.55.

Moderna Price Performance

Shares of MRNA stock opened at $122.13 on Tuesday. The company has a quick ratio of 3.91, a current ratio of 4.03 and a debt-to-equity ratio of 0.04. The business’s fifty day simple moving average is $105.61 and its 200-day simple moving average is $94.76. Moderna, Inc. has a 12-month low of $62.55 and a 12-month high of $142.79.

Moderna (NASDAQ:MRNA) last released its earnings results on Thursday, May 2nd. The company reported ($3.07) earnings per share (EPS) for the quarter, beating the consensus estimate of ($3.59) by $0.52. Moderna had a negative return on equity of 20.10% and a negative net margin of 115.82%. The firm had revenue of $167.00 million for the quarter, compared to the consensus estimate of $93.26 million. During the same period in the prior year, the firm earned $0.19 EPS. The firm’s revenue was down 91.0% on a year-over-year basis. As a group, analysts expect that Moderna, Inc. will post -7.47 earnings per share for the current year.

Insider Activity at Moderna

In related news, Director Noubar Afeyan sold 15,000 shares of the company’s stock in a transaction on Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the transaction, the director now directly owns 2,026,931 shares of the company’s stock, valued at approximately $224,827,186.52. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. In other Moderna news, CFO James M. Mock sold 647 shares of the stock in a transaction dated Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $61,186.79. Following the sale, the chief financial officer now directly owns 4,300 shares of the company’s stock, valued at approximately $406,651. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Noubar Afeyan sold 15,000 shares of the stock in a transaction dated Wednesday, May 1st. The stock was sold at an average price of $110.92, for a total value of $1,663,800.00. Following the sale, the director now directly owns 2,026,931 shares in the company, valued at $224,827,186.52. The disclosure for this sale can be found here. Insiders have sold a total of 139,954 shares of company stock valued at $14,822,576 in the last ninety days. Company insiders own 15.20% of the company’s stock.

About Moderna

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.